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The early and mid-term results of carotid artery 
stenting in high-risk patients
Woo-Sung Yun, Woo-Hyung Kwun, Bo-Yang Suh
Department of Surgery, Yeungnam University College of Medicine, Daegu, Korea
Purpose: This study aimed to investigate early and mid-term outcomes of carotid artery stenting (CAS). Methods: We retro-
spectively reviewed 111 patients who were treated for carotid stenosis between October 2004 and December 2009 (42 CASs 
and 69 carotid endarterectomies [CEAs]). Results: CAS group was older than CEA group (70 years vs. 67 years, P = 0.001). 
Coronary artery disease and high lesion above the 2nd cervical vertebral body were more common in CAS group (29% vs. 
13%, P = 0.002; 4% vs. 24%, P = 0.004). The 30-days stroke rate was higher in CAS group (10% vs. 1% in CEA group, P = 0.067, 
Fisher’s exact test). New brain lesions on diffusion-weighted magnetic resonance imaging were more common in CAS group 
(48% vs. 20% in CEA group, P = 0.002, chi-square test). The 1-, 3-year freedom from stroke were 91%, 84% in CAS group and 
99%, 99% in CEA group (P = 0.007, log-rank test). Univariate analysis showed that female gender and age ＞70 years were re-
lated with postprocedural neurological complications (P = 0.046 and P = 0.007, log-rank test). However, none were in-
dependent risk factors on multivariate analysis. Conclusion: In our series, the rates of peri-procedural neurological complica-
tions in CAS group were significantly high. These results suggest that more experience and restricted patient selection will be 
needed for CAS.
Key Words: Carotid artery stenosis, Stents, Endarterectomy, Stroke
INTRODUCTION
Through large randomised controlled trials (RCTs), car-
otid endarterectomy (CEA) has been positioned as a gold 
standard of treatment in patients with carotid artery 
stenosis to prevent ischemic stroke [1-4]. Along with the 
advancement of endovascular treatment, carotid artery 
stenting (CAS) was introduced as a potential alternative to 
CEA during the past two decades. Possible benefits of CAS 
are less invasiveness (available in patients with high-risk 
morbidity, quicker recovery, lower wound complication), 
lower incidence of cranial nerve injury, coverage of entire 
length of carotid lesion, feasible in inaccessible lesion by 
CEA, feasibility in hostile neck (prior neck surgery or radi-
ation) [5].
Among several RCTs comparing CEA vs. CAS in pa-
tients with atherosclerotic carotid disease, some reported 
the non-inferiority of CAS to CEA [6], while others failed 
to prove it [7,8]. And some studies are still ongoing [9-11]. 
Therefore, current practice guidelines recommend CAS as 
a possible alternative treatment to CEA only in patients 
with severe carotid stenosis and high operative risk [12, Woo-Sung Yun, et al.
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13].
In this study, we aimed to investigate early and mid- 
term outcomes of CAS in our hospital and to compare 
them with those of CEA. And we attempted to determine 
the risk factors of stroke after CAS.
METHODS
Between October 2004 and October 2009, 113 patients 
with atherosclerotic carotid artery stenosis underwent pri-
mary carotid artery intervention. One hundred eleven pa-
tients were enrolled in this study excluding 2 patients who 
underwent emergency CAS and thrombolytic therapy of 
the middle cerebral artery occlusion. The indications of 
surgical or endovascular treatment were: 1) ＞70% asymp-
tomatic carotid artery stenosis, 2) ＞80% asymptomatic 
stenosis, and 3) ＞50% stenosis with ulcerative plaque. 
Carotid stenosis percentage was determined angiographi-
cally according to North American Symptomatic Carotid 
Endarterectomy Trial criteria. Regardless of the type of ul-
cer, ulcerative plaque was diagnosed by 2 radiologists if 
there was evidence, on at least 1 angiographic view, that 
was considered likely to be an ulcer. During pre-treatment 
evaluation, all patients were categorized into high or low 
risk group. High risk was defined as clinically significant 
cardiac disease (congestive heart failure, unstable angina 
or need for urgent heart surgery), severe pulmonary dis-
ease, high lesion above the 2nd cervical vertebral body, 
previous radical neck surgery or ipsilateral carotid sur-
gery, previous cervical radiation, contralateral recurrent 
laryngeal nerve palsy, presence of a tracheostomy stoma, 
contralateral carotid occlusion. For high-risk group, CAS 
was preferred. CAS was performed in 42 patients (CAS 
group, 38%) and CEA was done in 69 patients (CEA group, 
62%). 
During CAS, predilatation was done in all patients. 
Brain protection device (BPD; FilterWire EZ system, 
Boston Scientific Co., Natick, MA, USA) was used in 41 pa-
tients (98%). Self-expendable stents were inserted in all 
cases; Closed-cell type (WALLSTENT, Boston Scientific 
Co.) was 22 (52%) and open cell type (PRECISE, Cordis 
Co., Hialeah, FL, USA) was 20 (48%).
All CEA was performed under general anesthesia and 
selective shunting using a Pruitt-Inahara carotid shunt 
(Number 2004-49; LeMaitre Vascular Inc., St. Petersbur, 
FL, USA). A carotid shunt was used if ＞  50% decrease in 
intraoperative electroencephalography amplitude and/or 
transcranial Doppler shows ＞  50% decrease in mean flow 
velocity of the ipsilateral middle cerebral artery when the 
internal carotid artery (ICA) was clamped. Eversion en-
darterectomy was done in 7 patients and conventional 
technique with primary closure was used for other 
patients.
Asprin (100 mg/day) and clopidogrel (75 mg/day) was 
prescribed for CAS patients from 3 days before treatment 
and CEA patients received aspirin (100 mg/day) alone. 
After treatment both groups received aspirin and clopido-
grel.
Postoperative neurologic evaluation was performed by 
a neurologist and diffusion-weighted brain magnetic res-
onance imaging (DW-MRI) was checked within a week. 
Clinical follow-up including duplex scans were done at 1 
month, 3 months, 6 months, and 12 months for the first 
year after treatment and annually thereafter on the basis of 
out-patient clinic by neurologists and vascular surgeons.
On the duplex scan, restenosis was defined as a 50% di-
ameter reduction of ICA combined with ICA peak systolic 
velocity greater than 125 cm/sec. If restenosis was de-
tected, further angiographic evaluation was indicated. 
Patient database and medical records were reviewed 
retrospectively.
Patient demographic data, early (≤30 days) and late (＞30 
days) complications and outcomes including hematoma, 
cranial nerve injury, hyperperfusion syndrome, intra-
cranial hemorrhage, stroke, myocardiac infarction and 
death were identified. Patient demographic data and early 
outcomes were compared between CAS and CEA group 
by t-test, chi-square test and Fisher’s exact test. Freedom 
from ipsilateral stroke was calculated by Kaplan-Meier 
method and compared by log-rank test. Multivariate anal-
ysis using Cox proportional hazard model was conducted 
to determine the risk factors of stroke after CAS.Carotid artery stenting in high-risk patients
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Table 1. Patient demographic and clinical data
CAS group CEA group
Characteristics  P-value
(n = 42)  (n = 69)
Age, mean (yr) 70 (56-79) 66 (50-78) 0.001
Gender, male 38 (91) 60 (87) 0.777
a)
Neurologic symptom 0.524
   Asymptomatic 11 (26) 22 (32)
   Symtomatic 31 (74) 47 (68)
Ulceration on plaque 12 (29) 17 (25) 0.647
High level stenosis 10 (24)   3 (4) 0.004
a)
Degree of stenosis 0.575
   50-79% 23 (55) 34 (49)
   80-99% 19 (45) 35 (51)
Smoking 16 (38) 33 (48) 0.317
Hypertension 33 (79) 54 (78) 0.969
Diabetes mellitus 16 (38) 20 (29) 0.320
Hyperlipidemia 12 (29) 22 (32) 0.713
Coronary artery disease 12 (29)   9 (13) 0.043
COPD   2 (5)   1 (1) 0.556
a)
Peripheral arterial disease   4 (10)   3 (4) 0.423
a)
Values are presented as number (%). 
CAS, carotid artery stenting; CEA, carotid endarterectomy; COPD,
chronic obstructive pulmonary disease. 
a)Fisher’s exact test.
Table 2. Early phase outcomes within 30 days
CAS group CEA group
 P-value
(n = 42)  (n = 69)
Ipsilateral stroke   4 (10)   1 (1) 0.067
a)
   Transient   3   1
   Disabling   1   −
Wound hematoma   1 (2)   1 (1) 1.00
a)
Cranial nerve palsy   −   2 (3) 0.525
a)
Hyperperfusion syndrome   1 (2)   1 (1) 1.00
a)
NBLs on DW-MRI 20 (48) 14 (20) 0.002
Values are presented as number (%). 
CAS, carotid artery stenting; CEA, carotid endarterectomy; NBL, 
new brain lesion; DW-MRI, diffusion-weighted magnetic resonance
imaging. 
a)Fisher’s exact test.
Fig. 1. Kaplan-Meier curves comparing freedom from ipsilateral 
stroke between the carotid artery stenting (CAS) and carotid endar-
terectomy (CEA) groups. 
Fig. 2. Kaplan-Meier curves comparing freedom from restenosis 
between the carotid artery stenting (CAS) and carotid endarterec-
tomy (CEA) groups. 
RESULTS
Patient demographic and clinical data are demon-
strated in Table 1. CAS group was older than CEA group 
(mean age, 70 vs. 66; P = 0.001, t-test) and coronary artery 
disease was more common in CAS group (29% vs. 13%, P 
= 0.043, chi-square test). There was no difference in other 
variables between the 2 groups. The mean follow-up dura-
tion was 25 months (range, 1 to 70 months).
Table 2 demonstrates early phase (≤  30 days) outcomes. 
30-day stroke rate was inferior in CAS group to CEA 
group, however it was not statistically significant (10% vs. 
1%, P = 0.067, Fisher’s exact test). Postoperative DW-MRI 
revealed new brain lesions (NBLs) in 48% of CAS group 
while in 20% of CEA group (P = 0.002, chi-square test). 
There was no 30-day mortality in both groups.
Regarding mid-term outcomes, 1-year, 3-year freedom 
from ipsilateral stroke was 90%, 83% in CAS group and Woo-Sung Yun, et al.
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99%, 99% in CEA group (P = 0.007, log-rank test, Fig. 1) and 
1-year, 3-year freedom from restenosis was 97%, 86% in 
CAS group and 96%, 89% in CEA group (P = 0.454, log- 
rank test, Fig. 2). Target lesion revascularization was done 
in 3 patients of CAS group and 4 patients of CEA group 
during the follow-up.
The univariate analyses between stroke negative group 
and stroke positive group was done with variables such as, 
age, sex, smoking, hypertension, diabetes mellitus, coro-
nary arterial disease, chronic pulmonary disease, cere-
brovascular disease, hypercholesterolemia, plaque status, 
amount of stenosis, level of stenosis, symptomatic or 
asymptomatic, stent type, cardiac risk factor, pulmonary 
risk factor, anatomical risk factor. The female gender and 
age ＞  70 years showed statistically significant differences 
(P = 0.046 and P = 0.007, log-rank test). However, no in-
dependent risk factor of ipsilateral stroke after CAS was 
identified on multivariate analysis.
DISCUSSION
The Stenting and Angioplasty with Protection in 
Patients at High Risk for Endarterectomy (SAPPHIRE) 
study showed promising results for CAS vs. CEA (12.2% 
vs. 20.1% in 1-year major adverse events, P = 0.004 for 
non-inferiority) [6]. Recently, authors reported no sig-
nificant difference in 3-year outcomes between 2 groups, 
such as freedom from major adverse event, freedom from 
death and freedom from stroke [14].
However, the Endarterectomy versus Stenting in 
Patients with Symptomatic Severe Carotid Stenosis 
(EVA-3S) trial was terminated early for safety and futility 
reasons because the 30-day stroke or death was sig-
nificantly higher in CAS group (9.6% vs. 3.9% in CEA 
group; relative risk [RR], 2.5; confidence interval [CI], 1.2 
to 5.1) [7]. However, after up to 4-year follow-up, the risk 
of ipsilateral stroke was similar in both groups after peri-
procedural period [15]. The authors concluded that CAS is 
as effective as CEA for middle-term prevention of ipsi-
lateral stroke, but the safety of CAS needs to be improved. 
The Stent-Supported Percutaneous Angioplasty of the 
Carotid Artery versus Endarterectomy (SPACE) trial also 
reported equivalent 2-year results of CAS compared with 
CEA even though it had failed to prove non-inferiority of 
CAS for the 30-day results [16]. CAS group also showed 
higher risk of stroke, death, or procedural myocardial in-
farction in the intention-to-treat analysis (8.5% vs. 5.2%; 
RR, 1.69; CI, 1.16 to 2.45) on short-term (≤ 120 days) re-
sults of the International Carotid Stenting Study that were 
recently reported [17].
In our study, perioperative stroke rates after CAS were 
higher than we expected (9% in asymptomatic patients, 
10% in symptomatic patients and 10% in total patients). It 
was higher than CEA group, although it was not statisti-
cally significant (10% vs. 1%, P = 0.067). It is assumed that 
the small sample size caused type II error. However, after 
perioperative period, the Kaplan-Meier curves of CAS and 
CEA groups are almost parallel as in the EVA-3S and 
SPACE study. This means mid-term stroke risk is similar 
between 2 groups and CAS can be a potential alternative to 
CEA if perioperative complications of CAS are reduced.
One of the causes which might explain the high peri-
procedural stroke rate after CAS is plaque instability. 
During CEA, not only plaque morphology but also plaque 
natures are visualized: smooth wall vs. irregular wall, soft 
plaque vs. hard plaque, ulcerative lesion, calcified lesion 
and plaque with hemorrhage. The vulnerable plaque is 
generally described as having a lipid core with a fibrous 
cap with thinning of the cap and inflammation in the 
shoulder region of the plaque [18]. In particular, when 
CAS is performed on vulnerable plaque or ulcerative pla-
que, there will be a high risk of embolization. Although a 
BPD is used, the guide wire and the device should be 
passed the lesion before. In this study, early stoke occurred 
more often in patients with plaque ulcers than without, 
even though it failed to make a significant difference (17% 
vs. 7%, P = 0.067, Fisher’s exact test). To identify a high-risk 
plaque, several techniques have been introduced. The 
Imaging in Carotid Angioplasty and Risk of Stroke study 
announced that carotid echolucency (the gray-scale me-
dian ≤ 25) increases the risk of stroke during CAS [19]. 
Other noble molecular imaging techniques, such as posi-
tron emission tomography, single photon emission com-
puted tomography, near-infrared fluorescence, and 
high-resolution MRI are introduced [20]. They may help-Carotid artery stenting in high-risk patients
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ful to select the candidates for CAS in the future, but cur-
rently, for further evidence, large clinical prospective trials 
are required.
After the SAPPHIRE trial, the United States (US) Food 
and Drug Administration approved the use of CAS for 
symptomatic patients who are considered high-risk surgi-
cal candidates. Use of CAS has been increasing since. 
Despite continuous effort and advancement in technology, 
early major adverse event rate is still high. Recent na-
tion-wide data in the US demonstrated that CAS had in-
creased rates of postprocedure stroke (1.8% vs. 1.1%, P ＜ 
0.05) and death (1.1% vs. 0.57%, P ＜  0.05) as opposed to 
CEA [21]. Some authors announced favourable outcomes 
after CEA even in “high-risk” patients [22-24]. One survey 
based on the American College of Surgeons National 
Surgical Quality Improvement Program database showed 
that CEA is associated with favourable 30-day outcomes 
across a spectrum of patient comorbidity features and on-
ly anatomic and technical features are independent pre-
dictors of perioperative stroke [25].
Another issue is NBLs after treatment. On meta-analy-
sis of 32 studies, the incidence of any NBLs on DW-MRI 
was significantly higher after CAS than after CEA (37% vs. 
10%, P ＜  0.01) [26]. And authors reported that the use of 
BPD (33% vs. 45% without, P ＜  0.01), closed-cell designed 
stents (31% vs. 51% with open-cell stent) during CAS and 
selective shunting (6% vs. 16% of routine shunting, P ＜ 
0.01) during CEA were protective factor of NBLs. In this 
study, CAS resulted in higher incidences of NBLs com-
pared with CEA (53% vs. 24%, P = 0.002). However, the sig-
nificance of microemboli is an unanswered question, 
currently. In a 2-year prospective study, 90% of the events 
were clinically silent [27].
A large prospective, population-based study demon-
strated that elderly people with silent brain infarcts on 
MRI are associated with higher risk of dementia and a 
steeper decline in cognitive function [28]. However, there 
are few studies investigating the relation between external 
cranial carotid artery revascularization and neuro-
psychological dysfunction [29,30]. Regarding the effect on 
cognitive function, microembolism during procedure 
may induce adverse effects while possibly inducing pos-
itive effects by increasing brain perfusion. For this ques-
tion, further study is needed.
The debate as to whether CAS is an alternative to CEA is 
ongoing. Our results showed unacceptable periproce-
dural stroke rates in CAS group. These results suggest that 
CEA should be the treatment of choice for patients with 
carotid artery stenosis and CAS should be performed with 
more restricted criteria in an experienced hospital. The 
limitations of this study are a retrospective design and 
small sample size.
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